Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer’s disease drug after it failed a late-stage study, sending shares of the drug developer plummeting 83% in early trading on Monday. The experimental treatment, simufilam, has been at the center of scrutiny after a medical professor linked to its development was charged with …
